Aug 15
|
Soleno Therapeutics stock falls after Scorpion Capital short report
|
Aug 11
|
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
|
Aug 11
|
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going
|
Aug 6
|
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 6
|
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
|
Jul 28
|
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
|
Jul 25
|
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
|
Jul 23
|
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
|
Jul 23
|
Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength
|
Jul 21
|
Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations
|
Jul 16
|
Exploring US High Growth Tech Stocks with Promising Potential
|
Jun 26
|
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
|
Jun 25
|
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
|
Jun 23
|
DoorDash, AMD upgraded: Wall Street's top analyst calls
|
Jun 20
|
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
|
Jun 20
|
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
|
May 26
|
EMA validates Soleno’s application for Prader-Willi syndrome treatment
|
May 23
|
Soleno Therapeutics seeking regulatory approval in treatment of PWS
|
May 23
|
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
|
May 22
|
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
|